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Abstract
This review highlights our investigations into the neuroprotective efficacy of estradiol and other
estrogenic agents in a clinically relevant animal model of transient global ischemia, which causes
selective, delayed death of hippocampal CA1 neurons and associated cognitive deficits. We find
that estradiol rescues a significant number of CA1 pyramidal neurons that would otherwise die in
response to global ischemia, and this is true when hormone is provided as a long-term
pretreatment at physiological doses or as an acute treatment at the time of reperfusion. In addition
to enhancing neuronal survival, both forms of estradiol treatment induce measurable cognitive
benefit in young animals. Moreover, estradiol and estrogen analogs that do not bind classical
nuclear estrogen receptors retain their neuroprotective efficacy in middle-aged females deprived of
ovarian hormones for a prolonged duration (8 weeks). Thus, non-feminizing estrogens may
represent a new therapeutic approach for treating the neuronal damage associated with global
ischemia.
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1. Introduction
Stroke is the third leading cause of death in the United States and the primary cause of
disabilities in adults [1;2;3]. Of the 600,000 new victims each year, 30% die and another
nearly 30% become severely and permanently disabled. Transient global ischemia arises as a
consequence of cardiac arrest, cardiac surgery, profuse bleeding, near-drowning and carbon
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monoxide poisoning and affects ~200,000 Americans each year [1;2;3]. Transient global
ischemia causes selective, delayed death of hippocampal CA1 neurons in humans and can
produce serious neurologic sequellae, of which cognitive deficits are most prominent. There
are still remarkably few safe and effective treatments to reduce the neuronal cell death and
cognitive dysfunction associated with ischemia. It is now well established that endogenous
and exogenous estrogens exert profound neuroprotective effects in animal models of focal
(stroke) and global ischemia [4;5;6;7;8;9;10;11;12;13;14]. Dietary intake of phytoestrogens
(plant-derived estrogens) can also improve outcomes after focal [15;16] and global ischemia
in rats [17]. In cultured neurons, estrogens can reduce cell death induced by excitotoxins
(e.g., glutamate), oxidative stress, β-amyloid, and serum deprivation
[18;19;20;21;22;23;24;25]. Moreover, estrogens are reported to reduce ischemia-induced
damage to tissues such as kidney and heart and to reduce apoptosis in vascular smooth
muscle [26;27;28;29;30]. A multicenter study of postmenopausal women also reported that
longer lifetime exposure to ovarian estrogens may protect against ischemic stroke [31].Thus,
estrogens hold great promise as potential therapeutic agents in treatment of ischemia. Yet,
the clinical use of estradiol and related estrogens in menopausal women remains
controversial. Large clinical trials such as the Women’s Health Initiative (WHI) and the
Heart and Estrogen/Progestin Replacement Study (HERS) called into question the ability of
hormone treatment to reduce the occurrence or incidence of cardiovascular disease, stroke
and dementia in postmenopausal women [32;33;34;35;36]. Another clinical trial, the
Women Estrogen Stroke Trial (WEST), reported no beneficial effects of estradiol on stroke
incidence; indeed postmenopausal women with estradiol treatment had an increased risk of
stroke and worse neurological outcomes [37]. The current situation underscores the
importance of animal studies to address unanswered questions regarding the efficacy of
hormone treatment to reduce the extent of ischemia-induced neuronal damage and
associated cognitive impairment.
Our laboratories initiated studies on the neuroprotective actions of the most abundant
ovarian estrogen, 17β-estradiol (hereafter referred to as estradiol), in animal models of
global ischemia about 10 years ago. Global ischemia induced by four vessel occlusion (4-
VO; see Figure 1A) in rats is possibly the best established animal model of global ischemia
[38]. A brief episode (10 min) induces selective death of CA1 pyramidal neurons and, as in
humans, results in delayed onset of cognitive neurological deficits [39]. Inhibitory
interneurons of the CA1 and virtually all neurons in the nearby CA2 or transition zone, CA3
and dentate gyrus survive. With the exception of a few scattered hilar neurons and/or
pyramidal neurons in cortex, other neurons do not exhibit cell death. Although the 4-VO
model virtually ablates hippocampal CA1 pyramidal neurons by 7 days, the onset of
histologically detectable neuronal death is delayed by 2–3 days [40], enabling molecular
studies of cells “destined to die” under conditions in which cell loss is not yet evident. This
model is also clinically relevant to global ischemia associated with cardiac arrest in humans
and offers the ability to compare changes in gene expression in neurons of the vulnerable
CA1 with those of the resistant CA3. Moreover, because blood circulation to the cranium is
completely blocked (rather than reduced by hypotension), monitoring of blood flow is not
necessary. It has not been possible to exploit the power of transgenic mice to study global
ischemia, because it is difficult to achieve delayed, selective hippocampal cell death in most
mouse strains.
At the time we began our work, there was limited evidence that estradiol reduced CA1
neuronal death and ameliorated the cognitive deficits associated with ischemic cell death
after global ischemia [41;42;43;44]. As described in the following review, we have now
explored a number of clinically relevant issues, including the timing and route of hormone
administration, the cellular and molecular mechanisms of estradiol’s neuroprotective
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actions, the degree to which neuronal preservation correlates with functional outcomes, and
the effects of age and prolonged hormone withdrawal.
2. Pretreatment with estradiol in young animals
We first examined the impact of estradiol administration on global ischemia induced
neuronal death in young adult male gerbils. The two vessel occlusion model in gerbils
affords a clinically relevant surgical model of global ischemia which is relatively simple and
requires a shorter duration of occlusion (5 min) relative to rats. To mimic the effect of long
term estradiol therapy in humans, we delivered estradiol to gerbils via subcutaneous, timed-
release pellets for 2 weeks prior to induction of ischemia. The pellets remain in place during
and after ischemia until the animals are killed for histological evaluation 7 days post-
ischemia. We found that estradiol administered at levels used for hormone therapy in
postmenopausal women intervenes in apoptotic death cascades (e.g., elevation of caspase-3
activity) in male gerbils and affords robust protection against ischemia-induced cell death in
hippocampal CA1 (Figure 2) [45]. We subsequently showed that 2-week pretreatment with
physiological levels of estradiol (30–60 pg/ml in rats, the range of circulating levels at
proestrus) attenuates ischemia-induced CA1 cell death in young, ovariectomized (OVX)
female gerbils and rats [46;47] (Figure 2). Thus, in agreement with others (see Introduction),
estradiol pretreatment is neuroprotective in young female and male rats and gerbils. Because
pharmacological agents and antibodies used to explore the cellular and molecular basis of
estrogen action and of cell survival pathways have not always been validated for use in
gerbils, almost all of the remaining studies we carried out involved OVX female rats.
2.1 Cellular and molecular mediators of estradiol protection
Estrogens produce their cellular actions, at least in part, by binding the classical estrogen
receptors ERα and -β, which were traditionally thought to function as ligand-activated
transcription factors (for reviews see [48;49]). Ligand activation of ERα and -β leads to
formation of a receptor dimer with high affinity for specific DNA sequences (estrogen
response elements) within the promoters of target genes. The ER dimer can also interact
with other DNA elements to regulate gene transcription, such as AP1 sites (known as the
“tethered” mechanism see [50;51;52]), and associate with coregulators that function as
transcriptional enhancers or repressors (see [53;54]). In addition to these genomic actions,
estrogens act via extranuclear signaling pathways to indirectly affect transcription of other
target genes [55;56]. Studies involving ERα and ERβ selective agonists and mice with
targeted deletions of ERα and ERβ indicate that ERα is critical for estradiol protection
against neuronal injury in animals undergoing middle cerebral artery occlusion (MCAO; see
Figure 1B), a focal ischemia model and clinically-relevant model of ischemic stroke in
humans [57]. This conclusion was confirmed in rats using pharmacological agents that
selectively target ERα and ERβ [58]. More recently, studies of mice in which ERα is
knocked out in specific cell types indicate that neuronal but not microglial ERα is required
for neuroprotection after MCAO in both male and female animals [59].
To evaluate the role of classical ERs as mediators of estradiol neuroprotection in a model of
global ischemia, we delivered the broad-spectrum ER antagonist ICI 182,780, a competitive
antagonist of estradiol binding to both classical ER isoforms, intracerebroventricularly (icv)
during the early post-ischemic period (at 0 and 12 h after reperfusion). Estradiol pellets were
implanted 2 weeks prior to ischemia and remained on board until rats were killed for
histological evaluation at 7 days after ischemia [47]. The classical ER antagonist ICI
182,780 abrogated estradiol-elicited neuroprotection (Figure 3B), consistent with a role for
classical ERs. To evaluate the role of ERα vs. ERβ, we administered subtype-selective
agonists daily for 2 weeks before and 7 days after ischemia. Both propyl pyrazole triol (PPT,
ERα-selective) and WAY 200070-3 (ERβ-selective) promoted survival of nearly all CA1
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pyramidal neurons in approximately 50% of the animals (Figure 3A), suggesting that
estradiol can act via ERα and ERβ to protect CA1 neurons from global ischemia-induced
death [47]. Studies from other investigators also implicate both ER subtypes in the
neuroprotective actions of estradiol when administered as a pretreatment for global ischemia
[7;60;61]. Therefore, the cellular mediators of estradiol’s neuroprotective actions appear to
differ for focal (ERα) and global ischemia (ERα and ERβ). Interestingly, both estradiol
administration and global ischemia markedly and selectively increased the abundance of
ERα protein in CA1, as assessed by Western blot analysis [47]. Similar increases in ERα
expression in cortical neurons have been reported after MCAO [62], suggesting that
increased expression of ERα may be a common response to brain ischemia.
We have also examined a role for the endogenous growth factor, insulin-like growth factor-1
(IGF1), as an essential co-mediator of estradiol’s neuroprotective actions. Both endogenous
and exogenous IGF1 act in the early post-ischemic period to reduce apoptotic neuronal cell
death (see [63]) and to promote vascular remodeling [64] after hypoxia-ischemia.
Considerable evidence implicates crosstalk between ER (primarily ERα) and IGF1 signaling
in the cellular actions of estradiol in the brain [12]. The physiological relevance of these
interactions is underscored by the observation that activation of brain IGF1 receptors is
critical to estrogen-dependent reproductive behaviors, neuroendocrine responses
[65;66;67;68;69], synaptic remodeling, neuronal differentiation and neuronal survival [12].
To examine a possible role for IGF1 receptor activation in estradiol protection of CA1
neurons, we administered the highly selective and potent IGF1 receptor antagonist referred
to as JB-1. JB-1 is a peptide analogue of IGF1 that mimics the recognition motif (“D
domain”) in the C-terminus of IGF1 that binds the IGF1 receptor [70]. JB-1 administered icv
at 0 and 12 h after ischemia abolished estradiol protection of CA1 neurons (Figure 3B).
These findings indicate that ongoing IGF1 receptor signaling is critical for protection by
estradiol pretreatment of hippocampal CA1 neurons against ischemia-induced cell death.
In the brain, estradiol [13;71;72;73;74] and IGF1 (for review, see [75]) act via their cognate
receptors to engage the mitogen-activated protein kinase (MAPK) and
phosphatidylinositol-3-kinase (PI3K) signaling pathways. Work from the laboratory of Luis
Garcia-Segura suggests that upon stimulation with estradiol, ERα and IGF1 receptors form a
macromolecular signaling complex in the plasma membrane, which recruits and activates
downstream kinases including MAPK [12;76;77]. Therefore, we examined the role of
MAPK signaling in estradiol neuroprotection in a rat model of global ischemia by icv
administration of the ERK/MAPK inhibitor PD98059 at 0 and 12 h after reperfusion [46].
As shown in Figure 3C, PD98059 reversed the protective effects of estradiol on CA1
neurons. Global ischemia also promotes rapid dephosphorylation and inactivation of the
p42/44 MAPK (ERK; Figure 4A,B) and the transcription factor cAMP-response element
binding protein (CREB; Figure 4C,D), assessed at 1 and 3 h after ischemia. Estradiol
pretreatment intervenes at the level of ERK/MAPK signaling to prevent ischemia-induced
dephosphorylation and inactivation of ERK and CREB, demonstrating that estradiol acts via
the classical ERs and IGF1 receptors, which converge on ERK/MAPK and CREB to
promote neuronal survival after global ischemia. Ischemia also activates the executioner
caspase-3 and downregulates the antiapoptotic protein Bcl-2, a known gene target of CREB
in CA1; estradiol pretreatment also reverses these responses to ischemia [46]. Interestingly,
blockade of ERK/MAPK does not prevent ischemia-induced downregulation of Bcl-2,
which may be a direct target of ERα. Hence, expression of Bcl-2 may be necessary but not
sufficient for neuronal survival in the face of global ischemia [46].
2.2 Estradiol pretreatment also improves functional outcomes after global ischemia
The data reviewed above clearly show that pretreatment of animals with physiological levels
of estradiol ameliorates hippocampal injury associated with global ischemia. Indeed this has
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been verified by many investigators over the past decade, and estradiol pretreatment appears
to regulate a large number of downstream effectors of neuronal survival after global
ischemia. This includes activation of ERK/MAPK, PI3K, and CREB, upregulation of Bcl-2,
BDNF and seladin-1 as well as inhibition of GSK-3β and dickkopf-1 (an antagonist of the
Wnt/β-catenin signaling pathway), attenuation of NADPH oxidase activity and reduction of
superoxide production [12;23;76;78;79;80;81;82;83;84]. Several of these mechanisms,
including roles for both ERα and ERβ, also pertain to neuroprotective actions of estradiol in
cultured hippocampal neurons exposed to excitotoxic glutamate [85;86]. Although much is
known about the impact of estradiol pretreatment on neuronal survival, its impact on
functional outcome assessed behaviorally is not as well studied. We investigated whether
our estradiol pretreatment paradigm improves ischemia-induced deficits in visual and spatial
working memory in young, OVX female rats. Global ischemia significantly impairs visual
and spatial memory, assessed by object recognition and object placement tests, when
assessed 6–9 days after injury (Figure 5). Estradiol reverses the impairment of visual
memory and also prevents ischemia-induced deficits in spatial memory tests with short (1, 7
min; Figure 5), but not longer (15 min) retention intervals. Thus, estradiol at near
physiological levels improves functional recovery after global ischemia [87]. Others have
shown improved performance in the Morris water maze, a classical test of hippocampal
function, in ischemic rats pretreated with estradiol [88;89]. An exciting report from another
investigator showed that a 15-day pretreatment with estradiol prior to ischemia rescued CA1
neurons and provided significant cognitive benefits, which lasted for 6 months after
ischemia [90]. These findings have important implications for intervention in the
neurological sequelae associated with global ischemia.
The results thus far indicate that estradiol pretreatment ameliorates global ischemia-induced
hippocampal damage and cognitive deficits. We are now beginning to assess the functional
integrity of hippocampal-based synaptic plasticity after ischemia. To address this issue, we
are measuring basal synaptic transmission and synaptic plasticity at CA1 synapses from
ischemic rats with or without estradiol pretreatment. As reported by others [91], our
preliminary results suggest that global ischemia significantly impairs basal synaptic
transmission at Schaffer collateral-CA1 synapses and abolishes long-term potentiation
(LTP) by 3 days after injury. Estradiol pretreatment prevents the ischemia-induced deficit in
both basal synaptic transmission and LTP (unpublished observations). Thus, both behavioral
and electrophysiological findings support the conclusion that long-term pretreatment with
estradiol at physiological levels improves the functional integrity of insulted hippocampal
CA1 pyramidal neurons.
3. Pretreatment with estradiol in older animals
Our findings and results from several independent laboratories cited above clearly show that
estrogens protect against global ischemia-induced hippocampal injury and improve
functional outcomes when administered to young animals. Rates of heart disease increase
substantially in postmenopausal women, placing them at increased risk for a global ischemic
event. The risk of cardiovascular disease is also increased in younger women who
experience ovarian hormone disruption as a consequence of premature ovarian failure or
functional hypothalamic amenorrhea [92;93]. Likewise, the Framingham Heart Study
showed that natural menopause before age 42 is associated with a significantly increased
risk of ischemic stroke [94]. Future stroke studies with measures of endogenous hormones
are needed to inform the underlying mechanisms so that novel prevention strategies for
midlife women can be considered. It is not clear that work carried out almost exclusively in
young animals will be predictive of outcomes in older animals or humans. The aging brain,
including the hippocampus, undergoes a myriad of biochemical, morphological and
functional changes that could alter the pattern of vulnerability to cerebral ischemia
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[95;96;97;98;99;100;101;102;103]. Brain cells of older animals exhibit changes including
ATP depletion, enhanced intracellular calcium, decreased ability to recover calcium
homeostasis, loss of mitochondrial homeostasis and increased propensity to form free
radicals [104]. Hippocampal synapses of aged female rats respond differently to estradiol
than do synapses in the young hippocampus [105;106], and this age-related difference in
morphological response to estradiol correlates with altered subcellular distribution of ERα
(reviewed in [107]). However, aged female rhesus monkeys retain the capacity to increase
spine density in response to estradiol [108]. In addition to direct actions on hippocampal
neurons, estrogens may affect hippocampal neurons indirectly via ERs expressed in basal
forebrain cholinergic neurons, which innervate the CA1 [109;110]. The actions of estrogens
on these circuits may also change with age, both in rats [111;112] and in rhesus monkeys
[113]. These circuits are important for memory, and it is notable that women begin to report
memory declines early in the menopausal transition [114;115]. Emerging data on estrogens
and memory in middle-aged and older rodents [116;117;118] as well as human and non-
human primates [114;119;120;121;122;123;124] point to the need for better understanding
of the interactions between age per se and loss of ovarian steroids on brain function.
A limited number of studies have examined models of cerebral ischemia in older animals. In
one study involving global ischemia in male rats, older (18–22 month) animals exhibited a
more pronounced loss of CA1 and striatal neurons than did younger (5–6 month) animals
[125]. In addition, there may be region-specific changes in vulnerability to global ischemia;
whereas the hippocampal CA1 is more vulnerable in younger animals, the striatum and
cortex may be more vulnerable in older rats [126]. There may also be an earlier appearance
and more severe progression of lesions in older rats [127]. In animal models of focal
ischemia, infarct volumes are greater in older animals [126;128]. However, estradiol
pretreatment reduces the volume of brain infarcts produced by focal ischemia (MCAO) in
middle-aged female rats that had been OVX for 1 week before experimentation [129;130]
and is still effective in older (16 mo) female rats [131]. In contrast, estradiol no longer
reduced the volume of infarcts in young females that were OVX for 10 weeks before insult
[132]. These findings raise the possibility that treatments such as estradiol, which are
effective in young animals, would not necessarily be effective in older animals, especially
after prolonged hormone deprivation.
It is imperative to answer these questions, as the ability of postmenopausal hormone therapy
to protect against the neuronal death associated with cardiac arrest or stroke remains
controversial. As noted above, the results of multicenter trials question the ability of
hormone therapy to reduce the occurrence or incidence of cardiovascular disease and stroke
in postmenopausal women [33;35]. Data from the WHI Memory Study (WHIMS) also
indicate that hormone treatment instituted years after menopause does not protect against
dementia or cognitive decline in elderly women [32;34]. One interpretation of the clinical
findings is that hormones initiated early in the menopause might provide neuroprotection,
whereas hormones initiated years after menopause may have no benefit or even cause harm
(“critical period hypothesis”) [133;134;135;136;137;138]. Indeed, reports in female rats
suggest that the ability of estradiol to prevent the effects of aging and ovarian hormone
withdrawal on cognition are abolished if treatment is delayed (e.g. for 5–10 mo) after OVX
[116;139]. Therefore, we have sought to ascertain whether there is such a critical period for
the neuroprotective actions of estradiol in global ischemia.
3.1 Estradiol pretreatment retains some neuroprotective actions in older rats
Whether estradiol retains its neuroprotective actions in middle-aged females, and the
relationship between aging and the prolonged absence of normal levels of ovarian hormones
in the outcome of global ischemia, were unanswered questions when we began our studies.
Also unknown was whether the age-related decline in IGF1, which engages in
Etgen et al. Page 6
Front Neuroendocrinol. Author manuscript; available in PMC 2012 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
physiologically relevant cross-talk with estrogens in the brain (see section 2.1), contributes
to ischemia-induced neurodegeneration and cognitive impairment during and after the
perimenopausal transition. We first evaluated the neuroprotective actions of estradiol
pretreatment in middle-aged (12–14 mo) female gerbils that were left intact or OVX and
treated with placebo or timed-release estradiol pellets for 2 weeks prior to ischemia. All
gerbils had substantial CA1 injury that was not significantly reduced by estradiol
pretreatment [140], raising the possibility that estradiol may not benefit older females.
However, a more recent study showed that a single high dose of estradiol (4 mg/kg),
administered 30 min before ischemia to 4, 9 or 18 month-old female gerbils that were OVX
for 2 weeks, produced comparable levels of histological protection at all ages [141]. Thus,
the dose or timing of hormone administration may be important in determining whether
estradiol retains its neuroprotective actions in older animals subjected to global ischemia.
To distinguish the impact of aging per se from the impact of the precipitous decline in
ovarian steroids, as occurs in menopausal humans, we next compared gonadally intact,
middle-aged female rats with females OVX in middle age to mimic human menopause. We
used females at 9–11 months that have been retired as breeders and hence are known to have
been fertile and reproductively active. In separate studies, we confirmed that when these
animals are OVX and injected with estradiol and progesterone to achieve blood steroid
levels equal to those in young (3–4 month) females, they have luteinizing hormone surges
that are significantly delayed and reduced in magnitude [69;142]. This impaired
neuroendocrine response closely parallels the situation in perimenopausal women [143].
We assessed both hippocampal CA1 neuron survival and behavioral performance in middle-
aged female rats that were left intact or OVX for 0, 1 or 8 weeks followed by estradiol
treatment using implantation of sustained release pellets [144]. One week after implantation
of estradiol or placebo pellets, females were tested on a battery of behavioral tests to
evaluate hippocampal-dependent cognition (object placement and object recognition) as well
as open field behavior, spontaneous alternation, and social preference. A significant
proportion of these older females had deficits in object placement and/or object recognition,
suggesting an effect of age on both aspects of working memory. Two weeks after the
initiation of estradiol or placebo treatment, animals underwent transient global ischemia or
sham surgery. One week after ischemia surgery, surviving animals were retested in all of the
behavioral paradigms, then perfused for histological analysis of hippocampal neuronal
survival. In agreement with observations in young animals, global ischemia produced
significant neuronal loss in the CA1 and impaired performance on visual and spatial
recognition tasks. Estradiol pretreatment significantly increased CA1 pyramidal neuron
survival in animals at all OVX durations (Figure 6). However, in marked contrast to findings
in young animals, the increased survival of hippocampal neurons was not associated with
improved cognitive performance on either the visual or spatial memory task. Therefore,
estradiol does retain some neuroprotective effects in older females, even after prolonged
hormone withdrawal, but the effects of estradiol pretreatment are different in middle-aged
than in young rats. Similar conclusions were reached in the study that compared OVX
female gerbils at different ages, which also showed age-related declines in novel object
recognition. However, these authors observed some cognitive benefit of estradiol when
administered as a high dose to older females just prior to ischemia [141].
Age-related decreases in IGF1 [145] predict increased cardiovascular mortality and
morbidity. Higher levels of IGF1 after ischemic stroke in humans are associated with
improved functional outcome [146] and inversely correlate with mortality at 3 and 6 months
[147]. There is also evidence that estradiol can increase rather than decrease cortical infarct
volume after endothelin-1-induced MCAO in reproductively aged females rats [148] and
that this may be due to age-related decreases in IGF1 [149]. Because our work in young
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females showed that ongoing brain IGF1 receptor activity is required for estradiol
neuroprotection, we examined whether increasing brain levels of IGF1 would reduce
neuronal death and enhance the ability of estradiol to rescue hippocampal neurons [150]. To
model the postmenopausal state in women, we again used middle-aged female rats that were
OVX for 8 weeks. They were implanted with an osmotic mini-pump delivering IGF1 or
saline into the lateral ventricle, and half of the rats also received pellets that delivered
physiological levels of estradiol. Two weeks later, rats were subjected to global ischemia or
sham operation. As expected, ischemia produced massive CA1 cell death evident at 14 days.
Significantly more neurons survived in animals treated with either estradiol or IGF1 alone,
and combined treatment produced no additive effect (Figure 7).
3.2 The critical period hypothesis and global ischemia
Taken together, our findings in middle-aged female rats subjected to transient global
ischemia provide little support for the critical period hypothesis. Estradiol pretreatment
reduces CA1 pyramidal cell death to the same extent in middle-aged females that are OVX
for 0, 1 or 8 weeks before experimentation. Moreover, the extent of cell rescue is similar to
that reported by us and others in young females (e.g., see Figures 2,3,6,7). Similarly, high
dose estradiol pretreatment was effective in reducing neuronal death and cognitive deficits
in 18-month-old gerbils, which are likely to have experienced a prolonged period of ovarian
hormone deprivation prior to experimentation [141]. Therefore, the aging female
hippocampus appears to retain its responsiveness to the neuroprotective actions of estradiol
when provided at high physiological or even pharmacological levels prior to global
ischemia. Although estradiol did not improve performance on tests of visual or spatial
working memory in rats, this was not related to the duration of hormone withdrawal and
hence more likely results from greater vulnerability of older animals to ischemia-induced
cognitive impairment. Wappler et al. [141] similarly reported more severe behavioral
deficits in older female gerbils subjected to ischemia, and estradiol was able to improve
behavioral performance in these older animals.
These results are in contrast to findings in a focal ischemia model, where injury is induced
by permanent occlusion of the MCAO with a suture. In this model, estradiol pretreatment
reduces the size of cortical infarcts in young female rats that are OVX for 1 week before
injury but not in females that are OVX for 10 weeks [132]. The loss of estradiol
neuroprotection in the long-term OVX females correlated with an impairment of estradiol
modulation of central and peripheral inflammatory mediators. Our observations with both
estradiol and IGF1 treatment in older females also differ from findings in the endothelin-1
model of MCAO. In the latter model, estradiol pretreatment actually increased infarct size in
middle-aged rats that were estrogen-deprived for approximately 5 weeks, and icv infusion of
IGF1 was neuroprotective in these animals only if estradiol was also provided [149]. Thus,
the critical period hypothesis may pertain to stroke-induced neuronal injury, but not to
transient global ischemia. Indeed early reports in the permanent MCAO model showed that
estradiol pretreatment was neuroprotective in middle-aged and older female rats that were
OVX for a brief period week insult [129;131]. Hence it is unlikely that age is the critical
factor. The different findings in focal and global ischemia may reflect fundamental
differences in the cellular and molecular mechanisms underlying neuronal death, in the
molecular step(s) at which estradiol intervenes to inhibit apoptosis after different types of
injury, and/or the brain regions involved. In focal ischemia, the cortex and striatum are the
primary sites of injury whereas hippocampal CA1 pyramidal neurons are most vulnerable
when the duration of global ischemia is brief. Other important considerations may be the
route and/or dose of hormone administration (for review see [151]). For example, our
studies employ a high physiological concentration of estradiol (30–60 pg/ml), a level that
would be achieved in intact females only during proestrus. There is a recent report that a 1-
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week pretreatment with very low levels of estradiol (approximately 10 pg/ml, which mimics
diestrus) was unable to reduce CA1 pyramidal cell death induced by transient global
ischemia in young female rats that were OVX for 10 weeks before experimentation whereas
this regimen was highly effective in rats that received estradiol at the time of OVX [82].
4. Acute treatment with estradiol after reperfusion
As described above, our experiments lead us to conclude that estradiol pretreatment (i.e.,
initiated 2 weeks prior to insult) significantly attenuates ischemia-induced neuronal death in
hippocampal CA1, and that the benefits of this treatment (at least with respect to neuronal
survival) are retained in older individuals even after prolonged ovarian hormone deprivation.
Nonetheless, such pretreatment regimens have limited translational potential for three major
reasons. First, the results of large clinical trials such as the WHI, HERS and WEST have led
to concerns that the risks of long-term ovarian hormone therapy in postmenopausal women
may outweigh the benefits. Second, long-term treatment with typical feminizing estrogens
(including the endogenous hormone estradiol) will never be applicable to aging men, who
comprise a significant fraction of individuals who are at high risk for global ischemia due to
cardiac arrest. Third, estradiol pretreatment may be either ineffective [152] or even
exacerbate neuropathology after transient global in diabetic animals [153]. Therefore, it is
critical to identify therapeutic strategies (1) that can be initiated after an ischemic event, (2)
that can be used in both men and women, and (3) that do not pose risks when used in
diabetic individuals. Below we summarize our recent work in OVX young and middle-aged
females treated acutely with estradiol and other estrogenic compounds at the time of
reperfusion.
4.1 Acute treatment with estradiol in young females
The demonstration that estradiol administered after an ischemic event is neuroprotective
would be of great clinical relevance. We first examined the ability of estradiol administered
immediately after global ischemia and reperfusion to protect hippocampal CA1 neurons in
young females OVX for 1 week. OVX female rats were subjected to global ischemia or
sham surgery and estradiol or vehicle was injected icv at 0 h after reperfusion. In our initial
experiments with 50 µg of estradiol, the hormone modestly but significantly reduced
ischemia-induced neuronal loss measured 8–9 days after ischemia [87]. These animals also
showed improved performance on object recognition (visual memory) tests, but not on
object placement (spatial memory) tests (Figure 8). Later studies confirmed these initial
observations [154], demonstrating marked increases in neuronal survival at 7 days after
ischemia in rats infused icv with 50 µg of estradiol (Figure 9). We now know that much
lower doses of estradiol (~2 µg) are also effective in this paradigm (see section 4.3).
4.2 Cellular and molecular mediators of acute estradiol neuroprotection in young females
We have carried out several experiments to characterize the receptor(s) and downstream
signaling pathways that mediate estradiol neuroprotection when given acutely after global
ischemia. As expected, the classical ER antagonist ICI 182,780 given icv concurrently with
estradiol can block the neuroprotective actions of acute estradiol (data not shown). However,
other observations suggest that the cellular and molecular mediators of estradiol protection
when administered after ischemia differ from those involved when estradiol is provided as a
long-term pretreatment. As shown in Figure 10, an ERα- but not an ERβ-selective agonist
mimics the actions of estradiol, and blockade of IGF1 receptors with JB-1 does not reverse
this form of protection. We next examined a role for PI3K/protein kinase B (Akt) signaling
in this form of estradiol protection. We administered estradiol (50 µg) in the presence or
absence of the PI3K inhibitor LY294002 at 0 h and 12 h after surgery [154]. LY294002 did
not detectably alter the number or appearance of surviving neurons in sham animals or in
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ischemic animals injected with vehicle, but abrogated the neuroprotective effects of estradiol
in CA1 (Figure 9). Global ischemia promoted early dephosphorylation and activation of
GSK-3β and the forkhead transcription factor FOXO3A, which are known Akt targets
whose inhibition promotes cell survival. Estradiol administered at the onset of reperfusion
also prevented ischemia-induced dephosphorylation and activation of GSK3β and FOXO3A,
and also prevented activation of caspase-3 [154]. These findings are in agreement with a
number of reports on estradiol neuroprotection both in vivo and in vitro. In addition, as
shown in Figure 11, acutely administered estradiol also maintained p-CREB in the early
postischemic period, similar to our findings with estradiol pretreatment. These findings
support a model whereby estradiol administered at the time of reperfusion works by
activation of PI3K/Akt signaling to maintain CREB activation, thereby promoting neuronal
survival in the face of global ischemia. They also suggest that ongoing activation of CREB
signaling may be a common downstream effector of estradiol protection when the hormone
is administered either before or after injury.
It is now clear that estrogens initiate rapid signaling events in neurons by binding to
recognition molecules other than the classical receptors ERα and ERβ. Estrogens alter the
excitability of neurons with latencies of a few seconds and stimulate Akt, MAPK and cAMP
production within minutes [24;25;74;155;156;157;158;159;160;161;162;163;164;165].
Many such rapid responses occur in cells lacking ERα and ERβ, and/or under conditions of
ERα and ERβ blockade (see [166;167;168]). Recent studies reveal the existence of
transmembrane receptors capable of responding to steroids with cellular activation. One
such receptor, GPR30, is a member of the G protein–coupled receptor superfamily and
mediates transcription-dependent and independent actions of estrogens
[169;170;171;172;173;174;175]. Estradiol exhibits an affinity for GPR30 similar to that for
ERα and ERβ, consistent with a role for GPR30 in the pleiotropic actions of estrogens on
neurons [176;177;178]. In cell lines, estradiol binding to GPR30 stimulates production of
cAMP, mobilization of calcium and activation of growth factor signaling
[172;173;179;180]. G1 is an agent that was identified by a combination of virtual and
biomolecular screening [176] as an agonist that binds selectively to GPR30, but not to
intracellular ERα and ERβ, which are thought to mediate the undesirable effects of long-
term hormone treatment in menopausal women.
Therefore, we evaluated the ability of estradiol and of the GPR30 agonist G1 to reduce
ischemia-induced CA1 pyramidal cell death when administered into the lateral ventricle
after ischemia [181]. We examined young female rats that were OVX for 1 week prior to
insult and administered vehicle, estradiol (2.2 µg) or the selective GPR30 agonist G1 (50
µg) as a single infusion at the onset of reperfusion. Animals were killed 7 days later, and
surviving CA1 pyramidal neurons were quantified as described above. As shown in Figure
12, animals subjected to ischemia and infused with vehicle suffered approximately 90% loss
of CA1 neurons when compared to sham-operated females. In contrast, 60–65% of CA1
neurons survived in females treated with a single infusion of either estradiol or G1 after
ischemia. This degree of neuron survival is equivalent to or even slightly better than that
observed in our work with long-term (2 week) estradiol pretreatment [46;47;144].
Certain electrophysiological effects of estradiol on hippocampal slices occur with a short
latency and are retained in slices derived from mice with genetic deletions of the classical
estrogen receptors. Therefore, we also compared the ability of estradiol and G1 to modify
CA1 neuron responses to excitatory inputs from the Schaffer collaterals recorded from
hippocampal slices in vitro. Slices were derived from young female rats that were OVX for
at least 1 week prior to experimentation. Application of either 100 nM estradiol or G1 to
hippocampal slices significantly increases the EPSC amplitude in ~60% of CA1 pyramidal
neurons in response to stimulation of the Schaffer collaterals [5]. The fraction of cells that
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responded is comparable to that reported for estradiol by other laboratories [156;182;183].
Pre-application of either estradiol or G1 occluded any further response to the other agent,
suggesting that they are acting at the same cellular target. Estradiol and G1 at 10 nM also
have identical effects on field EPSPs recorded in the CA1 pyramidal cell layer [181]. These
findings suggest that GPR30 or some as yet unidentified target of G1 may mediate the
neuroprotective actions of estradiol when given acutely after ischemia.
4.3 Similarities and differences between long-term and acute estradiol protection
Our work in young, OVX female rats demonstrates that estradiol administered as a single
injection immediately after global ischemia is as effective as long-term hormone
pretreatment in promoting survival of CA1 pyramidal neurons. The acute estradiol treatment
also attenuates ischemia-induced cognitive dysfunction, albeit perhaps not as effectively as
the long-term pretreatment regimen. Moreover, our data are consistent with the
interpretations: (1) that extranuclear estrogen receptors may mediate the neuroprotective
actions of estradiol when administered in proximity to an ischemic event and (2) that
persistent activation of CREB signaling in the early hours after ischemia may be a common
downstream effector of estradiol protection when the hormone is administered either as a
long-term pretreatment or acutely after insult. These conclusions are similar to those reached
by an independent laboratory that administered two membrane-impermeable estradiol
conjugates to young, OVX females rats 60 min before 10 min 4-VO [89]. Both compounds
rescued a significant fraction of CA1 pyramidal neurons and improved behavioral outcomes
in treated animals. Similar to our findings, the protective effects of conjugated estradiol were
blocked by ICI 182,780 and by a PI3K inhibitor, and neuroprotection was associated with
increased p-CREB in the CA1. Raval et al. [184] also reported that the neuroprotective
actions of estradiol in global ischemia induced by carotid artery occlusion and systemic
hypotension were accompanied by increased hippocampal p-CREB and CREB mRNA.
Interestingly, GPR30 is also reported to mediate the protective effects of estradiol during
myocardial ischemia-reperfusion, and this action is PI3K-dependent [185]. Moreover,
extranuclear ERα was recently implicated in the reendothelialization of the carotid artery in
OVX female mice [186]. Thus, extranuclear ERα and GPR30, perhaps in part via PI3K
activation, may contribute to cardioprotective as well as neuroprotective actions of estradiol.
Nonetheless, even though histological analysis suggests that long-term and acute estradiol
rescue approximately equal number of hippocampal neurons, our findings clearly suggest
that the underlying mechanisms may be distinct. Estradiol can act via either ERα or ERβ
when provided as a long-term pretreatment, and co-signaling through brain IGF1 receptors
is required (Figure 3). In contrast, an ERα but not an ERβ agonist is neuroprotective when
given after ischemia, and the ability of acute estradiol to improve hippocampal neuron
survival is not dependent on IGF1 receptor signaling in the early post-ischemic period
(Figure 10). Moreover, the GPR30 agonist G1, like estradiol, significantly reduces CA1
pyramidal cell death when given as a single injection at the onset of reperfusion (Figure 12).
One possibility is that either non-nuclear ERα or GPR30 can mediate this form of
protection. This conclusion would be similar to those drawn in a recent study on estradiol’s
protective actions against glutamate excitotoxicity in a hippocampal cell line [187]. These
investigators reported that estradiol, the ERα-selective agonist PPT and G1 attenuated
glutamate-induced neurotoxicity in at least one cell line. An ERβ agonist was ineffective,
and the protective actions of estradiol were reversed by either ICI 182,780 or a selective
GPR30 antagonist. Alternatively, it is possible that GPR30 or an as yet unidentified target of
estradiol, G1 and ERα-selective agonists may mediate the neuroprotective actions of
estradiol when given acutely after ischemia. Therefore, the cellular identity of the estradiol
recognition site(s) that mediate neuroprotection when the hormone is given after ischemia
remains to be determined.
Etgen et al. Page 11
Front Neuroendocrinol. Author manuscript; available in PMC 2012 August 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
4.4 Acute treatment with estradiol in older females
It is essential to determine whether estrogenic compounds administered after ischemia are
neuroprotective in older animals if such treatments are to be translated into the clinical
arena. As described above, our work with chronic estradiol pretreatment in middle-aged
female rats showed that hormone pretreatment reduced CA1 pyramidal cell death following
global ischemia even when females were deprived of ovarian hormones for 8 weeks by
surgical OVX. Therefore, we investigated whether acute administration of estradiol and of
estrogenic compounds that do not bind to ERα and ERβ are neuroprotective in older animals
after prolonged hormonal withdrawal [181]. We tested estradiol and 2 other compounds, G1
and STX, in middle-aged females that were OVX for 8 weeks before ischemia. STX is a
diphenylacrylamide compound that does not bind ERα or ERβ but that mimics short latency
estradiol modulation of hypothalamic ion channels through the activation of a G-protein
coupled receptor (for review see [167]). Middle-aged female rats that were OVX for 8
weeks underwent 10 min global ischemia and were then injected icv with a single dose of
estradiol (2.2 µg), G1 (50 µg) or STX (50 µg) immediately upon reperfusion. As shown in
Figure 13, the number of surviving CA1 pyramidal neurons at 7 days was significantly
increased in ischemic animals treated with estradiol, G1 or STX. All three compounds
promoted survival of approximately 50% of CA1 pyramidal neurons.
Because it is not feasible to administer estradiol or other compounds directly into the brain
after ischemia in humans, we also determined whether estradiol would rescue CA1 neurons
when administered systemically (subcutaneous) in middle-aged females that were OVX for
8 weeks before injury [181] (Figure 13). We used a dose (100 µg/kg) that was reported by
Simpkins and colleagues [188] to reduce infarct size after MCAO in rats when injected
subcutaneously 30 min after the onset of MCAO. The number of surviving CA1 pyramidal
cells was significantly increased in ischemic animals injected subcutaneously with estradiol,
and did not differ significantly from the neuroprotection provided by icv administration of
estradiol, G1 and STX. Our findings in older females indicate 1) that early post-ischemic
treatment with estradiol, G1 and STX promotes significant and comparable neuroprotection
in a clinically relevant model of global ischemia, 2) that non-classical ERs, perhaps G
protein-coupled receptors, mediate the neuroprotective actions of these compounds, and 3)
that the aging hippocampus retains it sensitivity to this form of neuroprotection even after
long-term hormone deprivation.
5. Conclusions and unresolved questions
This review described the strategies we adopted over the past decade to investigate the
neuroprotective efficacy of estradiol and other estrogenic agents in animal models of
transient global ischemia, summarized our key findings and discussed these in relationship
to published work from other investigators. In agreement with a vast literature in rodents and
in cultured neurons, we find that estradiol rescues a significant number of CA1 pyramidal
neurons that would otherwise die in response to global ischemia, and this is true when
hormone is provided as a long-term pretreatment at high physiological doses or as an acute
treatment at the time of reperfusion. Moreover, both regimens of hormone administration
continue to rescue hippocampal neurons in middle-aged females that are OVX for 8 weeks
before study to precipitate the prolonged ovarian hormone withdrawal that characterizes
human menopause. This suggests that for neuronal damage induced by global ischemia,
there may not be a critical time window in the early post-menopause in which estrogens
must be administered to retain benefit. However, this conclusion cannot be extrapolated to
other forms of neurodegeneration, cognitive aging or even focal ischemia at this time (for
review see [138]). Also notable is that in addition to providing histological neuroprotection,
both forms of estradiol treatment induce measurable cognitive benefit in younger animals.
However, the extent of functional protection with estradiol pretreatment in older females is
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not clear (e.g., see sections 3.1 and 3.2 as well as data from rats in [144] and from gerbils in
[141]) and may require modification of traditional behavioral tasks to accommodate age-
related declines in cognitive performance in a subset of older animals (see e.g., [102]).
Because of this concern, we have not yet evaluated the effects of acutely administered
estradiol, G1 or STX in older females subjected to prolonged hormone withdrawal.
The beneficial effects of a single injection of estradiol administered immediately after insult
on neuronal survival and cognitive function, and the ability of agents such as G1 and STX to
reduce hippocampal cell death, suggest that development of non-feminizing estrogens may
lead to new therapeutic approaches for treating the neuronal damage associated with global
ischemia. It is noteworthy in this regard that recent studies of isolated hearts from old (23–
24 month) OVX rats showed that the selective ERα agonist PPT reduces ischemic injury in
the aged, estrogen-deficient heart when administered 45 min before ischemia. This study
provided evidence that PPT acted via a non-genomic mechanism involving subcellular
redistribution of ERα and PKC activation [189]. As cardiac arrest (and hence global
ischemia) is much more prevalent in older patients, including postmenopausal women, our
finding that estradiol and related estrogens retain their efficacy in middle-aged females
tested 8 weeks after OVX is highly relevant. Especially promising for future translational
studies is our demonstration that estradiol is as effective in older, hormone-withdrawn
females when given systemically (subcutaneous) as when infused icv (Figure 13). Yet to be
determined is the effective time window for post-ischemic administration of estradiol or
other estrogen analogs. In a model of focal ischemia (permanent MCAO), high doses of
estradiol were able to reduce infarct volume in about one-third of rats when given as late as
6 h after the onset of ischemia [188]. This same group has also provided evidence that
several non-feminizing estrogens are neuroprotective in focal ischemia [11,21].
It will also be important to assess whether estradiol is neuroprotective in males, including
older males, when administered after global ischemia. We believe that this is an extremely
important area for future research, especially in view of recent data in male mice subjected
to cardiac arrest and cardiopulmonary resuscitation (CA/CPR). Sustained administration of
an ERβ agonist for 3 days after CA/CPR (10 min) in male mice reduced hippocampal injury,
and both estradiol and the ERβ agonist (but not PPT, the ERα-selective agonist) improved
neuronal survival in the striatum [61]. The same group reported that estradiol also reduced
kidney damage in both male and female mice after CA/CPR; these actions were observed in
ERα and ERβ null mice, suggesting that they are independent of the classical ERs [29].
There are also many unanswered questions about the cellular and molecular pathways
downstream of estradiol binding to its initial recognition site, be it a classical ER located
within the cell or at the plasma membrane or a transmembrane receptor such as GPR30.
Several different kinases, including ERK/MAPK and PI3K/Akt (see sections 2.1, 4.2 and
[12]), have been implicated in focal and global ischemia by several laboratories. There is
also a report that estradiol’s ability to reduce hippocampal damage after MCAO is
accompanied by decreased hyperphosphorylation of tau and decreased interaction of tau
with another kinase, GSK3β, which is downstream of PI3K/Akt [190]. In addition to these
kinases, there is evidence that protein kinases C and G may contribute to the
cardioprotective actions of estradiol in global ischemia (e.g., [191;192]). These pathways
may be especially important in maintaining mitochondrial integrity, which may play a
critical role in the ability of estrogens to attenuate ischemia-induced neuronal death and to
delay the progression of chronic neurodegenerative diseases (see [193;194] for recent
reviews).
In addition, we have not yet evaluated the potentially important contributions of glia and
neuroinflammation to ischemia-induced neuronal death and its reversal by estrogens. As
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summarized in a recent review [195], glia as well as neurons are direct targets of estrogen
action, and accumulating evidence implicates astrocytes and microglia as mediators of the
neuroprotective actions of estradiol in ischemic injury. Estradiol modulates inflammatory
processes in female rodents subjected to focal ischemia [132;196], and these actions may be
especially important in older individuals (e.g., see [4]), who are likely to have elevated basal
levels of inflammation due to obesity and other age-related diseases. There is also a report
that the GPR30 agonist G1 can decrease the production of pro-inflammatory cytokines and
reduce disease severity in an animal model of multiple sclerosis [197]. Thus, it is possible
that non-feminizing estrogens will have beneficial anti-inflammatory properties.
Another question ripe for exploration is the contribution of hippocampal neurogenesis and
its modulation by estrogens in long-term recovery from global ischemia. The subventricular
zone of the hippocampal dentate gyrus generates neuronal precursors in adult rodents, and
these newly born neurons can be integrated into hippocampal circuits [198;199]. Ischemia
and other insults enhance hippocampal neurogenesis in both rodents and primates (reviewed
in [200;201;202]); this response to ischemia is retained, although reduced, in aged rats
[203]. Estrogens have complex, sex-dependent effects on hippocampal neurogenesis
[204;205], and estradiol and IGF1 interact in the brain of young adult rats to enhance
neurogenesis in the dentate gyrus [206]. Estradiol can restore proliferation in the dentate of
mice with type I diabetes, a state characterized by reduced IGF1 as well as insulin
[207;208]. The neuroprotective actions of estradiol in focal ischemia have already been
linked to enhanced neurogenesis (reviewed in [10;12]). Therefore, it could be very
informative to investigate the effects of neuroprotective estrogenic compounds on
hippocampal neurogenesis, especially in older animals.
Finally, estradiol may act directly or indirectly to counter ischemia-induced epigenetic
alterations. In the past few years, several studies have shown that ischemia promotes
epigenetic remodeling and silencing of genes implicated in neuronal survival. Estrogenic
compounds may exert their neuroprotective action, at least in part, by epigenetic remodeling
and activation of these genes, thereby countering the impact of ischemia. Our recent findings
demonstrate that global ischemia activates the RE1 gene silencing transcription factor
(REST) [209;210], which acts by epigenetic remodeling to silence an array of genes critical
to neuronal function and survival such as the AMPA receptor subunit GluR2 [209], the μ-
opioid receptor [210], and the NMDA receptor subunit NR2B (unpublished observations).
Many of the gene targets of REST are activated by CREB. Others are putative targets of
STAT3 signaling. Chan and colleagues showed that focal ischemia suppresses STAT3
expression, recruitment of STAT3 to the manganese superoxide dismutase (MnSOD)
promoter and MnSOD transcription, resulting in overproduction of superoxide anion (O2−),
which contributes to ischemia-induced neuronal death [211]. These findings are consistent
with a role for STAT3-dependent epigenetic remodeling of its target MnSOD in ischemic
injury. It will be of interest to examine whether estradiol can act via ERα, CREB or STAT3
to promote epigenetic modifications and counter ischemia-induced epigenetic modifications
and silencing of prosurvival genes. Finally, ischemic preconditioning (a short ischemic
episode that affords neuroprotection) activates polycomb proteins in mature hippocampal
neurons [212]. Polycomb proteins act through epigenetic gene silencing to eradicate
potential mediators of neuronal death and promote cellular arrest, enabling mature neurons
to survive ischemic stroke [213]. Because protection by ischemic preconditioning and
estradiol share many commonalities, it would be of interest to examine the impact of
estradiol on polycomb proteins and epigenetic remodeling of polycomb target genes
implicated in neuronal death.
Research Highlights
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• Estradiol pretreatment attenuates ischemia-induced death of hippocampal
neurons.
• Estradiol given immediately after ischemia is highly neuroprotective.
• Estradiol treatment improves cognitive outcomes after global ischemia.
• Estrogens retain their neuroprotective efficacy in hormone-withdrawn older
females.
• The transcription factor CREB may be a downstream mediator of estradiol
protection.
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Figure 1.
Diagrams of the cerebrovascular anatomy of rats and methods for inducing global and focal
ischemia.
(A) The permanent electrocauterization of the vertebral arteries (1) and the position of the
surgical clips in the common carotid arteries (2) in a four-vessel occlusion (4-VO) model.
Transient global ischemia is induced in a two-stage process. On day 1, the vertebral arteries
are coagulated (1). This procedure does not block cerebral blood flow but prevents collateral
circulation to the forebrain during the carotid artery clamp on day 2. Twenty-four hours after
vertebral artery coagulation, transient global ischemia is induced by occluding the common
carotid arteries (2) for 10 min followed by reperfusion. Sham-operated rats undergo
vertebral artery coagulation and all other surgical procedures except for carotid artery
occlusion. (B) An intraluminal suture is used for middle cerebral artery occlusion (MCAO)
in the focal ischemia model. CCA, common carotid artery; ECA, external carotid artery;
ICA, internal carotid artery; MCA, middle cerebral artery; VA, vertebral artery. Adapted
from [214].
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Figure 2.
Estradiol pretreatment affords neuroprotection against global ischemia-induced neuronal
death in young males as well as females and in rats as well as gerbils.
Toluidine blue staining of coronal brain sections at the level of the dorsal hippocampus at 7
days after reperfusion from male gerbils (A–F), ovariectomized female gerbils (G–L) and
ovariectomized female rats (M–R) treated with estradiol or placebo for 14 days and
subjected to global ischemia or sham operation. Global ischemia induced significant cell
loss in the CA1 pyramidal cell layer; little or no cell loss was apparent in CA3 or dentate
gyrus (B, E, H, K, N,Q). Estradiol pretreatment for 14 days afforded significant
neuroprotection against ischemia-induced damage (C, F, I, L, O, R). Hippocampal injury in
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male gerbils was assessed quantitatively by the grading scale of Pulsinelli and Brierley: 0 =
no neurons damaged; 1 = a few (< 30%) neurons damaged; 2 = many (30–70%) neurons
damaged; and 3 = the majority of (> 70%) neurons damaged [38]. Neuronal damage scores
from a minimum of four microscopic sections per animal were analyzed; comparisons
among group means were made using ANOVA followed by Newman-Keuls test and plotted
as scatter graphs (S). Neuronal damage scores from two hormone-treated gerbils with low
plasma estradiol levels, indicating likely loss of the implanted pellet, are shown as
diamonds. In female gerbils and rats, the number of surviving pyramidal neurons per 250-
µm length of the medial CA1 pyramidal cell layer was counted bilaterally in 4 sections per
animal. The results were expressed as mean ± SEM. Statistical comparisons were made
between groups using ANOVA followed by Newman-Keuls test (T). DG, Dentate gyrus; so,
stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bars: lower
magnification, 400 µm; higher magnification, 60 µm. **, P < 0.01 vs. sham; ‡, P < 0.01
ischemia+estradiol vs. ischemia. Data from male gerbils are reproduced with permission
from [45] Jover et al., J. Neurosci., March 15, 2002, 22 (6):2115–2124. Data from female
gerbils and rats are reproduced with permission from [46] Jover-Mengual et al.,
Endocrinology 148 (2007) 1131–1143 (Copyright 2007, The Endocrine Society).
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Figure 3.
Classical estrogen receptors (ER) and IGF1 receptors mediate neuroprotective actions of
estradiol pretreatment.
(A) ERα (PPT) and ERβ (WAY) agonists elicit neuroprotection in some rats after global
ischemia. Rats were injected daily with vehicle (V), PPT or WAY for 14 days prior to
undergoing global ischemia or sham surgery. Hormonal treatments were continued until rats
were euthanized 7 days after ischemia or sham operation. Sham operated rats are
represented by open symbols, and ischemic rats are represented by filled symbols. The
median number of surviving pyramidal cells for each treatment group is demonstrated by a
horizontal line, and differences between groups were analyzed by Fisher’s exact test.
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(Ischemia + V vs. Sham + V,*** P<0.001; PPT+Ischemia vs. PPT+Sham, * P<0.04; WAY
+Ischemia vs. WAY+Sham,** P<0.02). Differences in the number of rats per group with
more than 40 surviving neurons after drug treatment and ischemia were analyzed using Chi
square (WAY+Ischemia vs. V+Ischemia, †, P = 0.04; PPT+Ischemia vs. V+Ischemia, #, P =
0.05). Data are reproduced with permission from [47] Miller et al., Endocrinology 146
(2005) 3070–3079 (Copyright 2005, The Endocrine Society).
(B) The ER antagonist ICI 182,780 and IGF1 receptor antagonist JB-1 block estradiol
protection. Ovariectomized female gerbils were treated with estradiol or placebo for 14 days
and subjected to global ischemia or sham operation. Animals received icv infusions of ICI
182,780, JB-1 or vehicle after ischemia. ICI 182,780 and JB-1 did not affect neuronal
survival in ischemic (two rightmost bars), but greatly reduced estradiol protection, assessed
at 7 days after surgery. Neither vehicle significantly altered neuronal survival vs. no
treatment in placebo- or estradiol-treated animals subjected to sham operation. Therefore,
vehicle and control data were pooled for purposes of illustration (grey bar labeled “sham”).
Similarly, neither vehicle significantly altered neuronal survival vs. no treatment in placebo-
treated animals subjected to global ischemia. Thus, these data were also pooled (white bar
labeled “ischemia+vehicle”). (**, P < 0.01). Data are reproduced with permission from [46]
Jover-Mengual et al., Endocrinology 148 (2007) 1131–1143 (Copyright 2007, The
Endocrine Society).
(C) The ERK/MAP kinase inhibitor PD98059 attenuates estradiol protection.
Ovariectomized female rats were treated with estradiol or placebo and subjected to global
ischemia (white and black bars) or sham operation (grey bars) as described above. Animals
received PD98059 (3 µg) or vehicle (10% DMSO) icv at 0 and 12 h after ischemia.
PD98059 greatly reduced estradiol protection, assessed at 7 days after surgery. **, P < 0.01
vs. all sham groups; ‡, P < 0.01 ischemia+estradiol vs. ischemia or ischemia+estradiol
+PD98059. Data are reproduced with permission from [46] Jover-Mengual et al.,
Endocrinology 148 (2007) 1131–1143 (Copyright 2007, The Endocrine Society).
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Figure 4.
Estradiol pretreatment rescues CA1 pyramidal neurons by activation of ERK/MAPK
signaling and maintenance of p-CREB.
(A,B). Estradiol prevents ischemia-induced dephosphorylation of ERK1 in CA1.
Representative Western blots (A) and relative abundance of p-ERK1 (B) in CA1 whole-cell
lysates from placebo- and estradiol-treated rats subjected to sham surgery or ischemia at 1
and 3 h after surgery. Subsets of animals were injected with PD98059 at 0 h and sacrificed
at 1 h after surgery. Westerns were probed with antibodies to p-ERK1/2 and ERK1/2.
Ischemia induced dephosphorylation of ERK1 (A, B). Estradiol significantly enhanced
ERK1 phosphorylation in shams and maintained levels of p-ERK1 in ischemic rats (B).
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PD98059 blocked the estradiol-induced increase in phosphorylation of ERK1 (A,B) in
control (sham) CA1. PD98059 also reversed the ability of estradiol to maintain ERK1
phosphorylation in post-ischemic CA1 (A,B). Values for ischemic rats were normalized to
the corresponding sham value. *, P < 0.05; **, P < 0.01.
(C,D.) Estradiol acts via MAPK signaling to prevent ischemia-induced CREB
dephosphorylation. Representative Western blots (C) and relative p-CREB abundance (D) in
the nuclear fraction of CA1 of placebo- and estradiol-treated rats subjected to sham
operation or ischemia at 1 and 3 h after surgery. Subsets of animals were injected with
PD98059 at 0 h and sacrificed at 3 h after surgery. Westerns were probed with antibodies to
p-CREB, CREB and histone 3 (nuclear marker). Ischemia promoted dephosphorylation of
CREB in the nuclei of CA1 neurons. Estradiol maintained the phosphorylated, activated
state of CREB in the CA1 of ischemic rats. PD98059 blocked the ability of estradiol to
maintain p-CREB levels in post-ischemic CA1. Values for experimental animals were
normalized to the corresponding sham value. **, P < 0.01.*, P < 0.05.
Data are reproduced with permission from [46] Jover-Mengual et al., Endocrinology 148
(2007) 1131–1143 (Copyright 2007, The Endocrine Society).
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Figure 5.
Estradiol pretreatment improves visual and spatial recognition memory performance in
young females rats subjected to global ischemia.
(A) Visual working memory was assessed by the object recognition task. Data are reported
as the exploratory preference score (novel object exploration / total object exploration, %; X
± SEM) for 3-min trials. At the 20 min retention interval, ischemic rats (Ischemia) exhibit
significantly impaired visual memory relative to sham-operated control rats (Sham).
Estradiol does not alter visual recognition memory scores in sham rats (Estradiol + Sham),
but reverses memory deficits in ischemic rats (Estradiol + Ischemia).
(B) Spatial working memory was assessed by the object placement task. Data are reported as
the exploratory preference score (displaced object exploration / total object exploration, %;
X ± SEM) for 3-min trials. At the 7 min retention interval, ischemic rats (Ischemia) show
impaired spatial memory relative to sham-operated rats (Sham). Chronic estradiol does not
significantly alter spatial working memory scores in sham rats (Estradiol + Sham), but
reverses the memory deficits in ischemic rats (Estradiol + Ischemia).
*, P < 0.05. Samples sizes are indicated within the bars.
Data are reproduced with permission from [87] Gulinello et al., Horm Behav 49 (2006) 246–
260.
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Figure 6.
Estradiol pretreatment reduces CA1 pyramidal cell loss in OVX, middle-aged females after
global ischemia.
Estradiol was provided for 2 weeks before ischemia or sham surgery as a timed-release
pellet as in Figures 2–5.
(A) Representative photomicrographs from the 1 week OVX interval of intact, OVX, and
OVX+estradiol (E) middle-aged female rats subjected to global ischemia or sham surgery.
At 12 days after reperfusion, viable neurons in 4 hematoxylin and eosin-stained sections
containing the dorsal hippocampal CA1 were counted in 3 sectors (lateral, middle, and
medial). Scale bars, Lower magnification (4×), 400 µm; higher magnification (40×), 60 µm.
(B) Data represent a grand sum across the 3 counting sectors and over right and left
hemispheres. Because no statistical difference was found among the different sham groups
(intact, OVX, OVX+E) at 1 and 8 wk after OVX, these animals were pooled into one sham
group. Global ischemia induced CA1 cell loss vs. sham-operated animals. Treatment with E
significantly increased CA1 cell survival. *, P < 0.01 compared to sham-operated rats, **, P
< 0.01 compared to intact and OVX rats.
(C) The data from ischemic animals in panel B presented for each OVX duration. There was
no significant impact of OVX duration on CA1 cell survival or estradiol protection in
middle-aged females subjected to transient global ischemia (10 min).
Data are reproduced with permission from [140] De Butte-Smith et al., Horm Behav 55
(2009) 442–453.
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Figure 7.
Estradiol and IGF1 pretreatment provide significant protection against CA1 cell loss caused
by global ischemia in middle-aged females subjected to prolonged hormone withdrawal (8
weeks OVX).
Estradiol was provided as a timed-release pellet as in Figures 2–5, and IGF1 was infused icv
using osmotic minipumps (see [150] for details). Viable neurons were counted in 3 sectors
(lateral, middle, and medial) in four hematoxylin and eosin stained sections of the dorsal
hippocampus. Data represent the grand sum (mean ± SD) of three counting sectors over both
the right and left hemispheres. Estradiol and IGF1 alone provided equivalent
neuroprotection, and their effects were not additive. *Significantly less than sham-operated
animals (P < 0.001). **Significantly greater than vehicle-treated ischemic animals (P <
0.001).
Data are reproduced with permission from [150] Traub et al., J Neuroendocrinol 21 (2009)
1038–1044.
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Figure 8.
Estradiol administered immediately after ischemia improves visual but not spatial
recognition memory performance in young females rats subjected to global ischemia.
(A) Visual recognition memory scores at a 20 min retention interval.
(B) Spatial recognition memory scores at a 7 min retention interval.
Data are reported as the exploratory preference score as defined in Fig. 5.
*, P < 0.05. Sample sizes are denoted on individual bars.
Data are reproduced with permission from [87] Gulinello et al., Horm Behav 49 (2006) 246–
260.
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Figure 9.
The PI3K inhibitor LY294002 attenuates acute estradiol protection. Ovariectomized female
rats were subjected to global ischemia (white and black bars) or sham operation (grey bars)
and infused icv with estradiol or vehicle immediately upon reperfusion. Animals also
received LY294002 or vehicle icv at 0 and 12 h after vehicle or estradiol injection. Global
ischemia induced extensive death of pyramidal cells in the hippocampal CA1 at 7 days post-
ischemia (I, M, J, N, Q), and estradiol significantly reduced neuronal death (K,O,Q).
LY294002 reversed estradiol protection, assessed at 7 days after surgery (L, P, Q). Scale
bars: lower magnification, 400 µm; higher magnification, 40 µm. so, stratum oriens; sp,
stratum pyramidale; sr, stratum radiatum.
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***, P < 0.001 vs. all sham groups; ##, P < 0.01 ischemia+estradiol vs. ischemia and ###, P
< 0.001 vs. ischemia + estradiol + LY294002.
Data are reproduced with permission from [154] Jover-Mengual et al., Brain Res 1321
(2010) 1–12.
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Figure 10.
Acute administration of an ERα selective agonist mimics the actions of estradiol. Young
female rats were ovariectomized for 1 week, subjected to global ischemia or sham operation,
and infused icv with the indicated agents immediately upon reperfusion. Ischemic control
females were infused with vehicle only (DMSO). Estradiol (2.2 µg) and the ERα agonist
16α-LE2 (50 µg) significantly reduced CA1 cell death, but the ERβ agonist 8β-VE2 (50 µg)
did not. The IGF1 receptor antagonist JB1 did not reverse estradiol protection. *P<0.01;
**P<0.05.
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Figure 11.
Estradiol administered acutely after global ischemia acts via PI3K signaling to maintain
CREB activation.
Ovariectomized female rats were subjected to global ischemia or sham operation and treated
with estradiol (2.2 µg) or vehicle immediately upon reperfusion. Subsets of animals were
injected with LY294002 immediately after estradiol or vehicle and killed 3 h after surgery.
Westerns were probed with antibodies to p-CREB and CREB.
(A) Representative Western blots of p-CREB and CREB in the nuclear fraction of CA1 of
vehicle- and estradiol-injected rats subjected to sham operation or ischemia and LY294002.
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(B) Quantification of relative p-CREB abundance at 3 h after ischemia. Estradiol maintained
the phosphorylated, activated state of CREB in the CA1 of ischemic rats. LY294002
blocked the ability of estradiol to maintain p-CREB levels in post-ischemic CA1. Values for
experimental animals were normalized to the corresponding sham value. *P<0.05 vs all
other groups,
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Figure 12.
The selective GPR30 agonist G1 affords neuroprotection when administered to young rats
immediately after ischemia.
(A) Representative photomicrographs of hippocampal neurons in the dorsal CA1 region 7
days after sham surgery or global ischemia (Isch) in young adult female rats that were OVX
for 1 week and injected icv with either estradiol (E2; 2.2 µg), G1 (50 µg) or vehicle
(DMSO) immediately after ischemia. Scale bars: low magnification, 400 µm; higher
magnification, 60 µm.
(B) Quantification of living pyramidal neurons in the CA1 region of the hippocampus 7 days
after ischemia. Neurons were counted in 3 sectors (lateral, middle and medial) of the dorsal
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hippocampus. * P < 0.001 vs. sham, ** P<0.001 vs. ischemia/vehicle. Data are reproduced
from [181] Lebesgue et al., PLoS One 5 (2010) e8642.
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Figure 13.
Estradiol (E2), the selective GPR30 agonist G1 and STX are neuroprotective when
administered immediately after ischemia in middle-aged female rats deprived of ovarian
hormones for 8 weeks.
(A) Representative photomicrographs of hippocampal neurons in the dorsal CA1 region 7
days after sham surgery or global ischemia in animals injected icv immediately after
reperfusion with either vehicle, E2 (2.2 µg), G1 (50 µg), STX (50 µg) or vehicle. Additional
animals were injected sc with E2 (100 µg/kg). Scale bars: low magnification, 400 mm;
higher magnification, 60 mm.
(B) Quantification of living pyramidal neurons in the CA1 region of the hippocampus 7 days
after ischemia. Neurons were counted in 3 sectors (lateral, middle and medial) of the dorsal
hippocampus. * P < 0.001 vs. sham, ** P<0.001 vs. ischemia/vehicle.
Data are reproduced from [181] Lebesgue et al., PLoS One 5 (2010) e8642.
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